Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Apoptosis, Necrosis, and Autophagy

Abstract C2: Clinical safety, pharmacokinetics and early evidence of activity of the oral IAPs inhibitor Debio 1143 in combination with carboplatin and paclitaxel: a phase Ib study

Isabelle Ray-Coquard, Christophe Le Tourneau, Nicolas Isambert, Carlos A. Gomez-Roca, Philippe Cassier, Marie Paule Sablin, Bruno Gavillet, Daniela Purcea, Elisabeth Rouits, Claudia Schusterbauer, Claudio Zanna, Pierre Fumoleau and Jean-Pierre Delord
Isabelle Ray-Coquard
1Centre Léon Berard, Départment de médicine carcinologique, Lyon, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Le Tourneau
2Institut Curie, Département d'oncologie médicale, Paris, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Isambert
3Centre Georges-Francois Leclerc, Service d'oncologie médicale, Dijon, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos A. Gomez-Roca
4IUCT Oncopole, Oncologie médicale, Toulouse, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Cassier
1Centre Léon Berard, Départment de médicine carcinologique, Lyon, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Paule Sablin
2Institut Curie, Département d'oncologie médicale, Paris, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Gavillet
5Debiopharm International SA, Lausanne, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Purcea
5Debiopharm International SA, Lausanne, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth Rouits
5Debiopharm International SA, Lausanne, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Schusterbauer
5Debiopharm International SA, Lausanne, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudio Zanna
5Debiopharm International SA, Lausanne, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Fumoleau
3Centre Georges-Francois Leclerc, Service d'oncologie médicale, Dijon, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Pierre Delord
4IUCT Oncopole, Oncologie médicale, Toulouse, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.TARG-15-C2 Published December 2015
  • Article
  • Info & Metrics
Loading
Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA

Abstract

Background: Resistance to apoptosis is a typical hallmark of cancer. Inhibitor of Apoptosis Proteins (IAPs) block caspase activation, modulate NF-kB signaling pathways, and are involved in resistance to standard chemo and radiation therapies. As such, IAPs antagonism represents an attractive target for therapeutic intervention. Debio 1143 is a potent orally-available monovalent SMAC mimetic antagonist of IAPs currently in clinical development. A previous phase I study showed Debio 1143 was well tolerated up to 900 mg QD as a single agent, with strong evidence of pharmacodynamic (PD) activity and appropriate pharmacokinetic (PK) disposition at doses ≥ 120 mg. [1] This Phase I study defined the dose limiting toxicities (DLTs), maximum tolerated dose (MTD), safety, PK, and PD of Debio 1143 in combination with carboplatin and paclitaxel.

Methods: Treatment-naïve and previously treated patients with squamous non-small cell lung cancer (NSCLC), and previously treated patients with triple negative breast cancer (TNBC) and platinum-resistant epithelial ovarian cancer (EOC) were treated with carboplatin (AUC 6) and paclitaxel 175 mg/m2 on day 1 of every 21-day-cycle up to a maximum of 6 cycles, combined with escalating doses of Debio 1143, administered once daily on days 1-5 of every 21-day cycle. The starting dose of Debio 1143 was 200 mg QD.

Results: Thirty-one patients were included in the study. Four patients are still on treatment. Hematological DLTs were observed in 2/4 patients in the first two dose levels despite the reduction of Debio 1143 dose to 100 mg. PK data suggested a PK interaction between Debio 1143 and paclitaxel. The study protocol was amended to reduce the doses of carboplatin to AUC 5 and paclitaxel to 135 mg/m2. Afterwards, patients received Debio 1143 doses of 100 mg (n = 2), 125 mg (n = 2), 175 mg (n = 2), 200 mg (n = 7), 225 mg (n = 5), 250 mg (n = 9). DLTs were febrile neutropenia (n = 2) and G3 ALT increase (n = 1). The MTD of Debio 1143 to be combined with carboplatin (AUC 5) and paclitaxel (135 mg/m2) is 250 mg QD. Most common treatment-related AEs reported in ≥ 15% of patients were asthenia (n = 13), decreased appetite (n = 11), diarrhea (n = 9), neutropenia (n = 9), thrombocytopenia (n = 8), anemia (n = 8), nausea (n = 7), fatigue (n = 7), vomiting (n = 4), AST increase (n = 4), hypomagnesaemia (n = 4), myalgia (n = 4),and epistaxis (n = 4). Paclitaxel exposure in patients dosed at 135 mg/m2 in combination with Debio 1143 was similar to historical control dosed at 175 mg/m2 due to a 25 to 40% reduction in clearance. Preliminary evaluation of PD endpoints confirmed Debio 1143-induced cIAP1 degradation in PBMCs at doses starting from 100mg. In line with the expected mechanism of action, modulation of serum PD markers of NF-kB signaling pathways and epithelial apoptosis was also observed during treatment. Twenty-three patients were evaluable for response. Partial responses by RECIST have been observed in 7 patients with EOC (6/17) and TNBC (1/5).

Conclusions: The combination of Debio 1143 with carboplatin and paclitaxel is well tolerated, with significant PD activity and hints of activity. The clinical PK interaction between Debio 1143 and paclitaxel is well-controlled and managed in the patients. These findings support a further Phase II program.

[1] HI Hurwitz et al., Cancer Chemother Pharmacol (2015) 75:851

Citation Format: Isabelle Ray-Coquard, Christophe Le Tourneau, Nicolas Isambert, Carlos A. Gomez-Roca, Philippe Cassier, Marie Paule Sablin, Bruno Gavillet, Daniela Purcea, Elisabeth Rouits, Claudia Schusterbauer, Claudio Zanna, Pierre Fumoleau, Jean-Pierre Delord. Clinical safety, pharmacokinetics and early evidence of activity of the oral IAPs inhibitor Debio 1143 in combination with carboplatin and paclitaxel: a phase Ib study. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C2.

  • ©2015 American Association for Cancer Research.
Previous
Back to top
Molecular Cancer Therapeutics: 14 (12 Supplement 2)
December 2015
Volume 14, Issue 12 Supplement 2
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract C2: Clinical safety, pharmacokinetics and early evidence of activity of the oral IAPs inhibitor Debio 1143 in combination with carboplatin and paclitaxel: a phase Ib study
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract C2: Clinical safety, pharmacokinetics and early evidence of activity of the oral IAPs inhibitor Debio 1143 in combination with carboplatin and paclitaxel: a phase Ib study
Isabelle Ray-Coquard, Christophe Le Tourneau, Nicolas Isambert, Carlos A. Gomez-Roca, Philippe Cassier, Marie Paule Sablin, Bruno Gavillet, Daniela Purcea, Elisabeth Rouits, Claudia Schusterbauer, Claudio Zanna, Pierre Fumoleau and Jean-Pierre Delord
Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) C2; DOI: 10.1158/1535-7163.TARG-15-C2

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract C2: Clinical safety, pharmacokinetics and early evidence of activity of the oral IAPs inhibitor Debio 1143 in combination with carboplatin and paclitaxel: a phase Ib study
Isabelle Ray-Coquard, Christophe Le Tourneau, Nicolas Isambert, Carlos A. Gomez-Roca, Philippe Cassier, Marie Paule Sablin, Bruno Gavillet, Daniela Purcea, Elisabeth Rouits, Claudia Schusterbauer, Claudio Zanna, Pierre Fumoleau and Jean-Pierre Delord
Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) C2; DOI: 10.1158/1535-7163.TARG-15-C2
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Apoptosis, Necrosis, and Autophagy

  • Abstract A021: Genipin enhanced apoptosis of gastric cancer by mitochondrial dysfunction and downregulation of Stat3/JAK2/Mcl-1 signaling pathway
  • Abstract A020: 1,7-Bis(4-hydroxyphenyl)-4-hepten-3-one from Betula platyphylla impairs autophagy and induces apoptosis in lung cancer cells
  • Abstract A019: Role of MTI-101 in disrupting calcium homeostasis leading to cell death in multiple myeloma
Show more Apoptosis, Necrosis, and Autophagy

Apoptosis, Necrosis, and Autophagy: Poster Presentations - Proffered Abstracts

  • Abstract A020: 1,7-Bis(4-hydroxyphenyl)-4-hepten-3-one from Betula platyphylla impairs autophagy and induces apoptosis in lung cancer cells
  • Abstract A019: Role of MTI-101 in disrupting calcium homeostasis leading to cell death in multiple myeloma
  • Abstract A018: Synergy between IAP inhibitors and a cytotoxic antibody-based chimeric protein in pancreatic cancer cells
Show more Apoptosis, Necrosis, and Autophagy: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement